Co-treatment with lenvatinib and CQ resulted in a more pronounced reduction in VEGFA levels in the K1 and BCPAP cell supernatants, and xenograft tumor models confirmed these findings [179], indicative of the cytoprotective nature of lenvatinib-induced autophagy. Here, VEGFA is linked to neoplasm.